New indication for Stivarga approved in Europe

7 August 2017

German pharma major Bayer (BAYN: DE) got a boost to its shares this morning after it revealed an important additional indication approval for its cancer drug Stivarga (regorafenib) in the European Union.

Bayer today announced the European Commission (EC) has granted marketing authorization for Stivarga for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with the company’s Nexavar (sorafenib). Stivarga is already approved and marketed for the treatment of colorectal cancer and gastrointestinal stromal tumors (GIST).

Regorafenib is the first and only licensed treatment that has demonstrated a significant improvement in overall survival (OS) in second-line HCC, the most-common form of liver cancer. The new approval marks the first licensed treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in patients with hepatocellular carcinoma previously treated with sorafenib.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK